精神医学64巻6号

2022年06月発行

特集 認知症診療の新潮流—近未来の認知症診療に向けて

認知症に対する治療のこれまでと現在—薬物治療を中心に

著者： 寺田整司¹

所属機関： ¹岡山大学学術研究院医歯薬学域精神神経病態学

ページ範囲：P.835 - P.848

抄録　本邦において，抗認知症薬4剤が臨床現場で使えるようになってから10年以上になる。その使用については賛否両論さまざまであるが，抗認知症薬の特性や副作用をよく知っておくことは，認知症診療に当たる医師にとって絶対に必要なことである。アルツハイマー病の根本治療を目指した取り組みは盛んであるが，成果が臨床の現場にはなかなか出てこないというのが現状である。認知症に対する治療のこれまでと現在の状況について，薬物治療中心にまとめる。

参考文献

1)Bowen DM, Smith CB, White P, et al：Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99：459-496, 1976

2)Davies P, Maloney AJ：Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2：1403, 1976

3)Perry EK, Perry RH, Blessed G, et al：Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1：189, 1977

4)White P, Hiley CR, Goodhardt MJ, et al：Neocortical cholinergic neurons in elderly people. Lancet 1：668-671, 1977

5)Perry EK, Tomlinson BE, Blessed G, et al：Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2：1457-1459, 1978

6)Whitehouse PJ, Price DL, Struble RG, et al：Alzheimer's disease and senile dementia：loss of neurons in the basal forebrain. Science 215：1237-1239, 1982

7)平井俊策：タクリンにみる米国における抗認知症薬の評価法．老年期痴呆 8：49-54, 1994

8)Summers WK, Majovski LV, Marsh GM, et al：Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315：1241-1245, 1986

9)Watkins PB, Zimmerman HJ, Knapp MJ, et al：Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271：992-998, 1994

10)Levy R, Eagger S, Griffiths M, et al：Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 343：176, 1994

11)Wilcock GK, Scott MI：Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 344：544, 1994

12)杉本八郎：アルツハイマー病治療薬塩酸ドネペジル開発経緯．有機合成化学協会誌 56：320-327, 1998

13)新井哲明，朝田隆：Rivastigmineの開発経緯．臨床精神薬理 14：1131-1135, 2011

14)Winblad B, Grossberg G, Frölich L, et al：IDEAL：a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69(4 Suppl 1)：S14-22, 2007

15)中村祐：Galantamineの開発経緯．臨床精神薬理 15：323-328, 2012

16)今埜博道：Memantine hydrochloride開発の経緯．臨床精神薬理 15：19-25, 2012

17)上田諭：認知機能より生活への注目を—「張り合い」と精神療法の重要性．精神経誌 118：424-429, 2016

18)大石智，宮岡等：Alzheimer病におけるSymptomatic Drugの有効性と副作用からみた評価．精神経誌 118：430-435, 2016

19)Birks JS, Harvey RJ：Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 6：CD001190, 2018

20)Birks JS, Chong LY, Grimley：Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 9：CD001191, 2015

21)Loy C, Schneider L：Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 1：CD001747, 2006

22)日本神経学会監修，「認知症疾患診療ガイドライン」作成委員会編：認知症疾患診療ガイドライン2017．pp224-229，医学書院，2017

23)笠貫浩史，新井平伊：認知症患者に対する薬物療法—抗認知症薬の使い分け，開始と中止のタイミング．精神科治療学 33：1191-1198, 2018

24)和田健二：現在使用可能な認知症治療薬の特徴と使い方．Current Therapy 37：798-803, 2019

25)針谷康夫，東海林幹夫：抗認知症薬4剤の特徴と比較．老年精医誌 30：610-617, 2019

26)Li DD, Zhang YH, Zhang W, et al：Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease. Front Neurosci 13：472, 2019

27)Moreta MP, Burgos-Alonso N, Torrecilla M, et al：Efficacy of acetylcholinesterase inhibitors on cognitive function in Alzheimer's disease. Biomedicines 9：1689, 2021

28)Thancharoen O, Limwattananon C, Waleekhachonloet O, et al：Ginkgo biloba Extract(EGb761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer's disease：a network meta-analysis. Drugs Aging 36：435-452, 2019

29)Zhang T, Liu N, Cao H, et al：Different doses of pharmacological treatments for mild to moderate Alzheimer's disease：a bayesian network meta-analysis. Front Pharmacol 11：778, 2020

30)Dou KX, Tan MS, Tan CC, et al：Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease：a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther 10：126, 2018

31)Buckley JS, Salpeter SR：A risk-benefit assessment of dementia medications：systematic review of the evidence. Drugs Aging 32：453-467, 2015

32)Feldman H, Gauthier S, Hecker J, et al：A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57：613-620, 2001

33)Herrmann N, Rabheru K, Wang J, et al：Galantamine treatment of problematic behavior in Alzheimer disease：post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 13：527-534, 2005

34)Bullock R, Bergman H, Touchon J, et al：Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 22：483-494, 2006

35)Niznik JD, Zhao X, He M, et al：Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing. Alzheimers Dement 16：630-640, 2020

36)Gauthier S, Loft H, Cummings J：Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine：a pooled data analysis. Int J Geriatr Psychiatry 23：537-545, 2008

37)Cummings JL, Schneider E, Tariot PN, et al：Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67：57-63, 2006

38)Grossberg GT, Manes F, Allegri RF, et al：The safety, tolerability, and efficacy of once-daily memantine(28mg)：a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 27：469-478, 2013

39)Martinez C, Jones RW, Rietbrock S：Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK：a cohort study. BMJ Open 3：e002080, 2013

40)McShane R, Westby MJ, Roberts E, et al：Memantine for dementia. Cochrane Database Syst Rev 3：CD003154, 2019

41)Seibert M, Mühlbauer V, Holbrook J, et al：Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments：a systematic review of controlled trials. Alzheimers Res Ther 13：131, 2021

42)Massoud F, Desmarais JE, Gauthier S：Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr 23：372-378, 2011

43)Sadowsky CH, Dengiz A, Olin JT, et al：Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 24：267-275, 2009

44)Chu CS, Yang FC, Tseng PT, et al：Treatment efficacy and acceptability of pharmacotherapies for dementia with Lewy bodies：a systematic review and network meta-analysis. Arch Gerontol Geriatr 96：104474, 2021

45)Tahami Monfared AA, Desai M, et al：Treatment options for dementia with Lewy bodies：a network meta-analysis of randomised control trials. Neurol Ther 9：521-534, 2020

46)Larsson V, Aarsland D, Ballard C, et al：The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 25：1030-1038, 2010

47)Kazui H, Adachi H, Kanemoto H, et al：Effects of donepezil on sleep disturbances in patients with dementia with Lewy bodies：an open-label study with actigraphy. Psychiatry Res 251：312-318, 2017

48)Knight R, Khondoker M, Magill N, et al：A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord 45：131-151, 2018

49)Russ TC, Morling JR：Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012：CD009132, 2012

50)Tricco AC, Ashoor HM, Soobiah C, et al：Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer's disease：systematic review and network metaanalysis. J Am Geriatr Soc 66：170-178, 2018

51)Zhang X, Lian S, Zhang Y, et al：Efficacy and safety of donepezil for mild cognitive impairment：a systematic review and meta-analysis. Clin Neurol Neurosurg 213：107134, 2022

52)Shi X, Ren G, Cui Y, et al：Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based on dosage in patients with vascular cognitive impairment：a network meta-analysis. Curr Alzheimer Res 19：133-145, 2022

53)Jin BR, Liu HY：Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment：systematic review and Bayesian network meta-analysis. Neural Regen Res 14：805-816, 2019

54)Battle CE, Abdul-Rahim AH, Shenkin SD, et al：Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments：a network meta-analysis. Cochrane Database Syst Rev 2：CD013306, 2021

55)Parsons C, Lim WY, Loy C, et al：Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev 2：CD009081, 2021

56)Hong YJ, Choi SH, Jeong JH, et al：Effectiveness of anti-dementia drugs in extremely severe Alzheimer's disease：a 12-week, multicenter, randomized, single-blind study. J Alzheimers Dis 63：1035-1044, 2018

57)Renn BN, Asghar-Ali AA, Thielke S, et al：Systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. Am J Geriatr Psychiatry 26：134-147, 2018

58)山﨑龍一，横井優磨：抗認知症薬はいつまで続けるべきなのか．臨床精神薬理 21：67-75, 2018

59)Herrmann N, Ismail Z, Collins R, et al：CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Alzheimers Dement(N Y)8：e12099, 2022

60)Blanco-Silvente L, Castells X, Saez M, et al：Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer's disease：a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol 20：519-528, 2017

61)Nordström P, Religa D, Wimo A, et al：The use of cholinesterase inhibitors and the risk of myocardial infarction and death：a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J 34：2585-2591, 2013

62)Zhu CW, Livote EE, Scarmeas N, et al：Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimers Dement 9：733-740, 2013

63)Wattmo C, Londos E, Minthon L：Longitudinal associations between survival in Alzheimer's disease and cholinesterase inhibitor use, progression, and community-based services. Dement Geriatr Cogn Disord 40：297-310, 2015

64)松﨑翔平，安高勇気，藤岡伸助，他：メマンチン塩酸塩投与による副作用発現の危険因子に関する後方視的調査．薬理と治療 46：1543-1548, 2018

65)Ruangritchankul S, Chantharit P, Srisuma S, et al：Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia：a comprehensive literature review. Ther Clin Risk Manag 17：927-949, 2021

66)Hong YJ, Han HJ, Youn YC, et al：Effects of body weight on the safety of high-dose donepezil in Alzheimer's disease：post hoc analysis of a multicenter, randomized, open-label, parallel design, three-arm clinical trial. Dement Geriatr Cogn Disord 50：289-295, 2021

67)Lee JH, Sevigny J：Effects of body weight on tolerability of rivastigmine transdermal patch：a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 25：58-62, 2011

68)Isik AT, Bozoglu E, Yay A, et al：Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease? Am J Alzheimers Dis Other Demen 27：171-174, 2012

69)Kim DH, Brown RT, Ding EL, et al：Dementia medications and risk of falls, syncope, and related adverse events：meta-analysis of randomized controlled trials. J Am Geriatr Soc 59：1019-1031.2011

70)Gill SS, Anderson GM, Fischer HD, et al：Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors：a population-based cohort study. Arch Intern Med 169：867-873, 2009

71)Isik AT, Soysal P, Stubbs B, et al：Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia：a meta-analysis and systematic review. J Am Geriatr Soc 66：1805-1811, 2018

72)Huang AR, Redpath CJ, van Walraven C：The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion：a retrospective, population-based, health administrative databases study in Ontario, Canada. BMC Neurol 15：66, 2015

73)Al-Hamed FS, Kouniaris S, Tamimi I, et al：Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients. Alzheimers Dement(N Y)7：e12184, 2021

74)Soysal P, Isik AT, Stubbs B, et al：Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia：a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 87：1368-1374, 2016

75)Tsuno N, Mori T, Ishikawa I, et al：Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease：the attitude towards food consumption in Alzheimer's disease patients revive with rivastigmine effects study. Geriatr Gerontol Int 19：571-576, 2019

76)Tamimi I, Ojea T, Sanchez-Siles JM, et al：Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients：a case-control study. J Bone Miner Res 27：1518-1527, 2012

77)Winblad B, Wimo A, Engedal K, et al：3-year study of donepezil therapy in Alzheimer's disease：effects of early and continuous therapy. Dement Geriatr Cogn Disord 21：353-363, 2006